Rubraca

FDA rejects Clovis' long-shot bid for approval of Rubraca
FDA rejects Clovis' long-shot bid for approval of Rubraca
Fierce Pharma
Clovis Oncology
Rubraca
FDA
bankruptcy
Flag link:
Clovis sells off remaining assets—including cancer drug Rubraca—for $70M-plus
Clovis sells off remaining assets—including cancer drug Rubraca—for $70M-plus
Fierce Pharma
Clovis Oncology
Rubraca
bankruptcy
Pharma & Schweiz
Flag link:
Amid bankruptcy, Clovis reveals more regulatory troubles for Rubraca
Amid bankruptcy, Clovis reveals more regulatory troubles for Rubraca
Fierce Pharma
Clovis Oncology
Rubraca
ovarian cancer
bankruptcy
Flag link:
In free fall, Clovis defaults on loan and agrees to further restrict Rubraca use
In free fall, Clovis defaults on loan and agrees to further restrict Rubraca use
Fierce Pharma
Clovis Oncology
Rubraca
FDA
ovarian cancer
Flag link:
With the walls closing in for Clovis, FDA demands ovarian cancer restriction for Rubraca
With the walls closing in for Clovis, FDA demands ovarian cancer restriction for Rubraca
Fierce Biotech
Clovis Oncology
Rubraca
ovarian cancer
FDA
Flag link:
Clovis Oncology flags possible bankruptcy in 'very near term'
Clovis Oncology flags possible bankruptcy in 'very near term'
NASDAQ
Clovis Oncology
bankruptcy
Rubraca
Flag link:
As Rubraca faces questions in ovarian cancer, Clovis trots out a prostate cancer partial win
As Rubraca faces questions in ovarian cancer, Clovis trots out a prostate cancer partial win
Fierce Pharma
Clovis Oncology
Rubraca
ovarian cancer
prostate cancer
Flag link:
Undeterred by FDA warning, desperate Clovis seeks Rubraca nod in front-line ovarian cancer
Undeterred by FDA warning, desperate Clovis seeks Rubraca nod in front-line ovarian cancer
Fierce Pharma
Clovis Oncology
Rubraca
FDA
ovarian cancer
Flag link:
Clovis, in need of cash or deals now to stem looming financial challenges, looks to pipeline for ideas
Clovis, in need of cash or deals now to stem looming financial challenges, looks to pipeline for ideas
Fierce Biotech
Clovis Oncology
Rubraca
ovarian cancer
funding
Flag link:
Why Clovis Oncology Stock Went Into Retreat Mode This Week
Why Clovis Oncology Stock Went Into Retreat Mode This Week
Motley Fool
Clovis Oncology
Rubraca
Flag link:
ASCO: Clovis CEO defends Rubraca's ovarian cancer win as FDA wants more assurance
ASCO: Clovis CEO defends Rubraca's ovarian cancer win as FDA wants more assurance
Fierce Pharma
ASCO 2022
Clovis
Rubraca
ovarian cancer
FDA
Flag link:
Clovis quietly unveils crippling FDA delay as its troubles deepen
Clovis quietly unveils crippling FDA delay as its troubles deepen
Fierce Pharma
Clovis Oncology
FDA
Rubraca
ovarian cancer
Flag link:
Clovis equity investors overlook two elephants
Clovis equity investors overlook two elephants
EP Vantage
Clovis Oncology
Rubraca
ovarian cancer
Flag link:
ASCO-GU – prostate cancer PARPS move to the front line
ASCO-GU – prostate cancer PARPS move to the front line
EP Vantage
prostate cancer
ASCO-GU
PARP inhibitors
Lynparza
Zejula
Rubraca
Talzenna
biomarkers
AstraZeneca
Merck
GSK
JNJ
Clovis Oncology
Flag link:
Why Clovis Oncology Shares Got a Bump This Week
Why Clovis Oncology Shares Got a Bump This Week
Motley Fool
Clovis Oncology
earnings
Rubraca
Flag link:
Clovis Oncology completes target enrollment in ATHENA trial in advanced ovarian cancer
Clovis Oncology completes target enrollment in ATHENA trial in advanced ovarian cancer
Pharmaceutical Business Review
Clovis Oncology
clinical trials
Rubraca
ovarian cancer
Opdivo
Bristol-Myers Squibb
Flag link:
Clovis steals march on AZ with PARP prostate approval
Clovis steals march on AZ with PARP prostate approval
Pharmaforum
Clovis Oncology
prostate cancer
Rubraca
FDA
Flag link:
From Gilead To AstraZeneca, Investors Should Watch These Biotech Giants Right Now
From Gilead To AstraZeneca, Investors Should Watch These Biotech Giants Right Now
Motley Fool
FDA
drug approvals
Gilead Sciences
remdesivir
AstraZeneca
Merck
Lynparza
Clovis Oncology
Rubraca
Bristol-Myers Squibb
Opdivo
Yervoy
Flag link:
Positive Prostate Cancer Results for Lynparza Are Bad News for Clovis Oncology
Positive Prostate Cancer Results for Lynparza Are Bad News for Clovis Oncology
Motley Fool
Clovis Oncology
Rubraca
AstraZeneca
Merck
Lynparza
prostate cancer
Flag link:
FDA Gives Clovis Oncology's Rubraca a Priority Review
FDA Gives Clovis Oncology's Rubraca a Priority Review
Motley Fool
Clovis Oncology
Rubraca
FDA
priority review
Flag link:

Pages